ETON PHARMACEUTICALS INC. - COMMON STOCK

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

01 May 2025 16:30:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

28 Apr 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

01 Apr 2025 07:00:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

18 Mar 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

14 Mar 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

04 Mar 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

03 Mar 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

07 Feb 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

06 Feb 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

03 Jan 2025 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

20 Dec 2024 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

17 Dec 2024 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

03 Dec 2024 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

25 Nov 2024 06:50:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

12 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

07 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

06 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

03 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

22 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

08 Aug 2024 16:01:00 By Nasdaq GlobeNewswire